Certolizumab Pegol Plus Methotrexate is Significantly more Effective than Placebo plus Methotrexate in Active Rheumatoid Arthritis

Certolizumab Pegol Plus Methotrexate
Is Significantly More Effective Than
Placebo Plus Methotrexate in Active Rheumatoid Arthritis: Findings of a Fifty-Two–Week, Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study

This activity has expired.
You will be redirected to our Rheumatology page shortly to find related content in this specialty.